The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
The company has contracted with a urologist, who will review customers' requests for tests, and prescribe the firm's epigenetics-based male fertility analysis.
The company's test measures epigenetic alteration of two genes using Qiagen PCR methods, in order to detect signs of recurrence in colorectal cancer patients post-surgery.
The Singapore-based molecular diagnostics firm plans to use the funds for regulatory approvals and commercialization of its lead epigenetics-based test for breast cancer.
The company plans to launch the new qNIPT test, which uses methylation-specific quantitative PCR to detect fetal epigenetic biomarkers, in the near future.
